Condition: Hepatocellular Carcinoma (HCC) · Sponsor: Zhongda Hospital
Tumor-draining lymph nodes play an important role in anti-tumor immune responses. In patients with hepatocellular carcinoma (HCC), however, the relationship between regional lymph node metastasis (LNM) and immunotherapy-based efficacy is unclear. This study aimed to evaluate whether extrahepatic LNM is associated with worse survival outcomes as compared to other metastatic sites in patients with advanced HCC.
This description comes directly from the study's public registry record.
Gao-Jun Teng, M.D · +86-02583272121 · gjteng@vip.sina.com
Hai-dong Zhu, M.D · +86-02583272121 · zhuhaidong9509@163.com
Always discuss trial participation with your own doctor first.
| Zhongda Hospital | Nanjing, Jiangsu, China | Completed |
| Zhongda Hospital | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06876753